IDL Diagnostics AB (publ)
STO: IDLDX.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Anders Hultman
- Employees
- 20
- Headquarters
- Stockholm, Sweden
- IPO year
- 2025
- Market cap
- SEK 76.0M
- Website
- https://idldiagnostics.com
Loading IDLDX…
Loading profile data…Frequently asked questions about IDLDX
What does IDL Diagnostics AB (publ) (IDLDX.ST) do?
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoi...
Where does IDLDX.ST trade?
IDL Diagnostics AB (publ) (IDLDX.ST) trades on the Stockholm Stock Exchange.
What sector is IDLDX.ST in?
IDL Diagnostics AB (publ) (IDLDX.ST) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of IDL Diagnostics AB (publ)?
Anders Hultman is the chief executive officer of IDL Diagnostics AB (publ) (IDLDX.ST).
Where is IDL Diagnostics AB (publ) headquartered?
IDL Diagnostics AB (publ) is headquartered in Sweden.
Does IDLDX.ST pay a dividend?
IDL Diagnostics AB (publ) (IDLDX.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IDLDX.ST go public?
IDL Diagnostics AB (publ) (IDLDX.ST) completed its initial public offering in 2025.